ArticleMolecular cancer research : MCR2021
Platelet-Coated Circulating Tumor Cells Are a Predictive Biomarker in Patients with Metastatic Castrate-Resistant Prostate Cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer research : MCR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
2.8field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 46 citations in OpenAlex.
- Towards liquid biopsy-based analysis of antitumour immunity.Nature reviews. Clinical oncology · 2026Review
- Exploring platelet-covered and naked circulating tumor cells - a single-cell transcriptomic perspective.Journal of translational medicine · 2026Article
- OpenIMC: an open-source platform for analyzing single-cell and spatial proteomics by imaging mass cytometry.BMC bioinformatics · 2026Article
- OpenIMC: an open-source platform for analyzing single-cell and spatial proteomics by imaging mass cytometry.Research square · 2026Article
- Wnt ligands in breast cancer metastasis: unraveling their dual roles and therapeutic potential.Molecular biology reports · 2026Review
- Circulating tumor cell and oncosome subtypes in portal and peripheral venous circulations may be used for diagnosis and prognostication of pancreatic cancer.NPJ precision oncology · 2025Article
- Characterizing circulating rare cells in peripheral blood for detecting and monitoring multiple myeloma and precursor states.NPJ precision oncology · 2025Article
- Caught in the Act: Tumor-Immune Interactions in Circulation of Patients with Immune Marker Positive Circulating Tumor Cells.Cancers · 2025Article
- Anti-tumour effects of perioperative ketamine in lung cancer: a non-randomised, exploratory biomarker study.British journal of anaesthesia · 2025Article
- Representation learning enables robust single cell phenotyping in whole slide liquid biopsy imaging.Scientific reports · 2025Article
- Article
- Simultaneous expression of epithelial and immune cell markers in circulating tumor cells identified in patients with stage 4 breast cancer.Communications medicine · 2025Article
- Unsupervised detection of rare events in liquid biopsy assays.NPJ precision oncology · 2025Article
- Contrastive Representation Learning for Single Cell Phenotyping in Whole Slide Imaging of Enrichment-free Liquid Biopsy.bioRxiv : the preprint server for biology · 2025Article
- Selective apoptosis of tumor-associated platelets boosts the anti-metastatic potency of PD-1 blockade therapy.Cell reports. Medicine · 2025Article
- Cells in the Polyaneuploid Cancer Cell State Are Prometastatic.Molecular cancer research : MCR · 2025Article
- Article
- Advances and potentials in platelet-circulating tumor cell crosstalk.American journal of cancer research · 2025Review
- Article
- Circulation of rare events in the liquid biopsy for early detection of lung mass lesions.Thoracic cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 1 country.
Shoujie ChaiConvergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California.ORCID 0000-0002-5621-8725
Nicholas MatsumotoConvergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California.
Ryan StorgardConvergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California.
Chen-Ching PengConvergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California.
Ana AparicioDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-0900-0923
Benjamin OrmsethConvergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California.
Kate RappardConvergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California.ORCID 0000-0002-0342-0014
Katherine CunninghamConvergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California.
Anand KolatkarConvergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California.ORCID 0000-0002-8621-1073
Rafael NevarezConvergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California.
Kai-Han TuConvergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California.
Ching-Ju HsuConvergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California.
Paymaneh MalihiConvergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California.
Paul CornDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Amado ZuritaDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-3805-7307
James HicksConvergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California.ORCID 0000-0001-5353-4338
Peter KuhnConvergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California. pkuhn@usc.edu ruizvela@usc.edu.ORCID 0000-0003-2629-4505
Carmen Ruiz-VelascoConvergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, California. pkuhn@usc.edu ruizvela@usc.edu.
Convergent Science (United States) · USUniversity of Southern California · USThe University of Texas MD Anderson Cancer Center · US
Funding
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4MNCI NIH HHS P30 CA014089
Abstract
Metastatic castration-resistant prostate cancer (mCRPC) includes a subset of patients with particularly unfavorable prognosis characterized by combined defects in at least two of three tumor suppressor genes:
Indexed as
Biomarkers, TumorHumansMaleNeoplasm MetastasisNeoplastic Cells, CirculatingProstatic Neoplasms, Castration-ResistantSurvival AnalysisBiomarkers, Tumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.